MyelinWatch EL

MYELINWATCH

Understand multiple sclerosis.

What MS is, how it presents, how it is diagnosed, and which treatments are available today. Follow emerging treatments and research into myelin repair, with clear explanations, sources, and a plain account of uncertainty.

Content last updated:

Where to start

What is MS?The basics in plain words, with the numbersTreatments available todayHow today's treatment options came aboutWhat's new in researchThe developments that matter, with their limits

Selected developments

Reviewed developments, with the evidence and limits shown.

Research event/source date:
Emerging treatmentsResults from peoplePhase 3: fewer relapses than with teriflunomide

REMODEL-1 and REMODEL-2: remibrutinib lowered relapse rates versus teriflunomide

The Lancet published the results on 23 October 2026: in two Phase 3 trials, adults with relapsing MS who took remibrutinib had fewer relapses than those who took teriflunomide.

Read the update →Source: The Lancet — PubMed indexed primary-article abstract ↗
Research event/source date:
Emerging treatmentsResults from peopleFDA application accepted for Priority Review, according to Roche

Fenebrutinib: Roche says FDA accepted MS application for priority review

Roche announced on 30 September 2026 that the FDA accepted its application for Priority Review.

Read the update →Source: Roche — official company announcement ↗